Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib-Based Therapy vs Standard FCR in Untreated Younger Patients With CLL
NCT02048813Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by National Cancer Institute. Started Mar 2014; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02048813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048813.